207231-24-1

Basic information

• Product Name: ethyl 4-chloro-6,7,8-trifluoroquinoline-3-carboxylate
• Synonyms: ethyl 4-chloro-6,7,8-trifluoroquinoline-3-carboxylate
• CAS NO: 207231-24-1
• Molecular Formula: C₁₂H₇ClF₃NO₂
• Molecular Weight: 289.6376896
• Mol File: 207231-24-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 4-chloro-6,7,8-trifluoroquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-chloro-6,7,8-trifluoroquinoline-3-carboxylate(207231-24-1)
• EPA Substance Registry System: ethyl 4-chloro-6,7,8-trifluoroquinoline-3-carboxylate(207231-24-1)

Safety Data

• Hazardous Substances Data: 207231-24-1(Hazardous Substances Data)

Upstream product

• 79660-46-1 ethyl 6,7,8-trifluoro-4-hydroxyquinoline-3-carboxylate 

Downstream Products

• 1442676-46-1 C₁₆H₁₁F₄NOS 

Relevant articles and documents

Development of a practical and efficient synthesis of SIPI-4884, a HMG CoA reductase inhibitor for the treatment of hypercholesterolemia

An improved process of the novel HMG CoA reductase inhibitor SIPI-4884 has been developed for early preclinical pharmacology and safety studies, and it was made up with an efficient nine-step and scalable process. Significant improvements in the nucleophi

Quinoline Compounds, Intermediates, Preparation Methods and Uses Thereof

A kind of quinoline compounds as formula A, pharmaceutical accepted solvates, optical isomers or polymorphisms thereof. The intermediates of formula D. in which, R1, R2 and R3 is independently H, halo or the subustitents o

THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES

The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABAA receptor and modulating GABAA, and use of the compound of formula I for the treatment of GABAA receptor associated disorders. The general structure of formula I is shown below and can exist in tautomeric forms: The invention further provides a method of modulation of one or more GABAA subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).

High affinity central benzodiazepine receptor ligands: Synthesis and structure-activity relationship studies of a new series of pyrazolo[4,3- c]quinolin-3-ones

A large series of 2-aryl(heteroaryl)-2,5-dihydropyrazolo[4,3-c]quinolin- 3-(3H)-ones, carrying appropriate substituents at the quinoline and N2- phenyl rings, were prepared and tested as central benzodiazepine receptor ligands. Results from structure-affinity relationship studies were in full agreement with previously proposed pharmacophore models and, in addition, quantitative structure-activity analysis gave further significant insight into the main molecular determinants of high benzodiazepine receptor affinity. The intrinsic activity of some active ligands was also determined and preliminary discussed.